2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-108229S
    6β-Naltrexol-d3 1435727-11-9 99.72%
    6β-Naltrexol-d3 (6β-Hydroxynaltrexone-d3) is deuterium labeled 6β-Naltrexol. 6β-Naltrexol (6β-Hydroxynaltrexone), the primary metabolite of Naltrexone, is a peripherally selective opioid antagonist. 6β-Naltrexol selectively inhibits gastrointestinal opioid effects in human subjects and inhibits Morphine-induced slowing of gastrointestinal transit.
    6β-Naltrexol-d3
  • HY-128853S
    Taurodeoxycholate-d6 sodium 2687960-92-3 99.4%
    Taurodeoxycholate-d6 sodium salt is a bile salt-related anionic detergent. Taurodeoxycholate-d6 sodium salt is formed in the liver by conjugation of deoxycholate with Taurine (HY-B0351). Taurodeoxycholate-d6 sodium salt is used for isolation of membrane proteins including inner mitochondrial membrane proteins. Taurodeoxycholate-d6 (TDCA) exhibits anti-inflammatory and neuroprotective effects.
    Taurodeoxycholate-d6 sodium
  • HY-17406S1
    Tolcapone-d4 1246816-93-2 99.13%
    Tolcapone-d4 (Ro 40-7592-d4) is the deuterium labeled Tolcapone (HY-17406). Tolcapone (Ro 40-7592) is a selective, potent and orally active COMT inhibitor with an IC50of 773 nM. Tolcapone can inhibits α-syn and Aβ42 oligomerization and fibrillogenesis. Tolcapone can cause oxidative stress and induce cancer cells apoptosis and ROS production. Tolcapone can be used for the researches of cancer and neurological disease, such as Parkinson disease and neuroblastoma.
    Tolcapone-d4
  • HY-17609S1
    Difelikefalin-d5 hydrochloride
    Difelikefalin-d5 (CR-845-d5) hydrochloride is the deuterium labeled Difelikefalin (HY-17609). Difelikefalin (CR-845) is a peripherally restricted and selective agonist of kappa opioid receptor (KOR). Difelikefalin produces anti-inflammatory effects and has the potential in modulating pruritus in conditions such as chronic kidney disease.
    Difelikefalin-d5 hydrochloride
  • HY-177646A
    Mivelsiran sodium
    Mivelsiran sodium is a siRNA targeted to amyloid-beta precursor protein (APP). It is used for the study of Alzheimer's disease.
    Mivelsiran sodium
  • HY-B2167S2
    Docosahexaenoic acid-13C4
    Docosahexaenoic acid-13C4 is 13C labeled Docosahexaenoic acid. Docosahexaenoic Acid (DHA) is an omega-3 fatty acid abundantly present brain and retina. It can be obtained directly from fish oil and maternal milk.
    Docosahexaenoic acid-13C4
  • HY-128850S1
    N-Acetyl-D-mannosamine-13C 875654-27-6 99.84%
    N-Acetyl-D-mannosamine-13C is the 13C labeled N-Acetyl-D-mannosamine. N-Acetyl-D-mannosamine (ManNAc) is an essential precursor of N-acetylneuraminic acid (NeuAc), the specific monomer of bacterial capsular polysialic acid (PA)
    N-Acetyl-D-mannosamine-13C
  • HY-12131
    DMP 696 202578-52-7 99.03%
    DMP 696 is a selective corticotropin-releasing hormone receptor 1 (CRHR1) antagonist, used for the treatment of anxiety and depression.
    DMP 696
  • HY-17615
    Fosnetupitant 1703748-89-3
    Fosnetupitant (Pronetupitant) a methylene phosphate proagent of Netupitant. Fosnetupitant (Pronetupitant) exhibits a pKi of 9.5 for human NK1 receptor.
    Fosnetupitant
  • HY-107713
    PPDA 684283-16-7 98.0%
    PPDA is a subtype-selective NMDA receptor antagonist that preferentially binds to NR2C/NR2D containing receptors.
    PPDA
  • HY-107732
    JNJ-5207787 683746-68-1 ≥98.0%
    JNJ-5207787 is a nonpeptidic, selective and penetrate the blood-brain barrier neuropeptide Y Y2 receptor (Y2) antagonist. JNJ-5207787 inhibits the binding of peptide YY (PYY) with pIC50s of 7.0 and 7.1 for human Y2 receptor and rat Y2 receptor, respectively. JNJ-5207787 is >100-fold selective versus human Y1, Y4, and Y5 receptors.
    JNJ-5207787
  • HY-108321
    Zofenopril 81872-10-8 98.81%
    Zofenopril is an angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 81 μM.
    Zofenopril
  • HY-109150
    Mesdopetam 1403894-72-3 98%
    Mesdopetam (IRL790) is a dopamine D3 receptor antagonist (Ki=90 nM; IC50=9.8 μM for human recombinant D3 receptor) with psychomotor stabilizing properties. Mesdopetam is used for the research of motor and psychiatric complications in Parkinson disease.
    Mesdopetam
  • HY-111419
    DSP-1053 1176326-76-3 99.75%
    DSP-1053, a benzylpiperidine derivative, is a potent Serotonin Transporter (SERT) inhibitor with a Ki of 1.02 nM. DSP-1053 shows partial 5-HT1A receptor agonistic activity with a Ki of 5.05 nM. DSP-1053 has antidepressant activity.
    DSP-1053
  • HY-111500
    (Rac)-NMDAR antagonist 1 2435557-99-4 98.0%
    (Rac)-NMDAR antagonist 1 is the racemate of NMDAR antagonist 1. NMDAR antagonist 1 is a potent and orally bioavailable NR2B-selective NMDAR antagonist.
    (Rac)-NMDAR antagonist 1
  • HY-112913
    SOCE inhibitor 1 2169316-15-6 99.73%
    SOCE inhibitor 1 (Compound 39) is a store-operated calcium entry (SOCE) inhibitor with an IC50 of 4.4 μM. SOCE inhibitor 1 has a good stability in plasma.
    SOCE inhibitor 1
  • HY-114814
    ORM-10921 free base 610782-82-6 98.08%
    ORM-10921 free base is a selective α-2C adrenergic receptor antagonist with a Ki of 1.4 nM. ORM-10921 free base displays potent antidepressant and antipsychotic-like effects.
    ORM-10921 free base
  • HY-123534
    CYT-1010 213769-33-6 99.28%
    CYT-1010 is a mu-opioid receptor agonist extracted from patent WO2013173730A2, with EC50s of 13.1 nM and 0.0053 nM on beta-arrestin recruitment and inhibition of cAMP production, respectively.
    CYT-1010
  • HY-124607
    (R)-BRD3731 2056262-08-7 98.22%
    (R)-BRD3731 is a GSK3 inhibitor extracted from patent US20160375006A1, compound example 273, has IC50s of 1.05 and 6.7 μM for GSK3β and GSK3α, respectively.
    (R)-BRD3731
  • HY-128656
    LML134 1542135-76-1 99.43%
    LML134 (compound 18b) is an orally active and high selective Histamine 3 receptor (H3R) inverse agonist with Kis of 0.3 nM and 12 nM for hH3R cAMP and hH3R bdg. LML134 penetrates the brain rapidly, leading to high H3R occupancy, and disengages its target with a fast kinetic profile. LML134 has the potential for excessive sleep disorders.
    LML134
Cat. No. Product Name / Synonyms Application Reactivity